EAP - 65% pain reduction in 10 OA patients in usa
Filed with ASX · · 6 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- New financial year update
- S&P DJI Announces June 2020 Quarterly Rebalance
- Block trade to institutional investors
- EAP treatment completed and Orphan Status achieved for MPS-I
- Reinstatement to Official Quotation
Later from Paradigm Biopharmaceuticals
- Quarterly Activities Report
- MPS receives critical approvals and feedback from agencies
- Appendix 4E and 2020 Annual Report
- Paradigm Presentation to Emerging Leaders Conference
- EMA provides key path toward phase 3 trials and registration
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals